{
    "symbol": "ERYP",
    "quarter": 2,
    "year": 2022,
    "date": "2022-09-13 11:15:04",
    "content": " With that, net loss for the first half of 2022 was EUR1 million, which is a EUR27 million improvements over the same period of last year and obviously, related mostly to the EUR24.4 million net capital gain on the sale of our production facility in Princeton. Operating expenses of EUR25.2 million were also showing a EUR6 million decrease, that's minus 19% year-over-year with a EUR5.9 million decrease minus 25% in R&D expenses, again related to the decrease in clinical development activities. Total operating expenses, including asset improvement provision of EUR2.5 million on Lyon production facility related to the ends of eryaspase operations, and a EUR1.9 million provision for restructuring and resizing -- also  just mentioned, related to the French operations. Income tax included also a provision as of June 30, 2022 of EUR3.7 million, that's actually $4.1 million, reflecting the best estimate to date of the tax impacts of the capital gain from the sale of the Princeton facility. This is a EUR19.6 million increase in cash position during the first half of '22, and that was the result of the net cash of EUR37 million, 30%, when EUR6 million received from the sale of the Princeton facility net cash inflow, EUR20.4 million of net cash utilization in operating and investing activities, obviously including the sale of the Princeton facility."
}